Sort   by:  
 Page size 
Chemotherapy-induced peripheral neuropathy (CIPN) is a debilitating, often dose-limiting, side effect of taxane-based chemotherapy, a cornerstone of breast cancer treatment. Despite its prevalence, no FDA-approved therapies exist for the prevention or treatment of CIPN, underscoring the need for mec...
ORGANISM(S): Mus musculus (Mouse) 
2026-08-13 | PXD074140 | Pride
The microtubule-stabilizing drug paclitaxel remains standard of care for various solid malignancies but frequently leads to chemotherapy-induced peripheral neuropathy (CIPN). CIPN is a leading cause for premature treatment termination and a significantly reduced quality of life in long-term cancer s...
ORGANISM(S): Homo sapiens (Human) 
2026-02-22 | PXD070094 | Pride
Longitudinal RNA sequencing of skin and DRG neurons in mice with paclitaxel-induced peripheral neuropathy
Chemotherapy-induced peripheral neuropathy (CIPN) is a major dose-limiting side effect of cancer treatment, yet the lack of predictive human models has hindered therapeutic progress. We have established a scalable model of paclitaxel-induced axon degeneration and neurotoxicity in iPSC-derived sensor...
ORGANISM(S): Homo sapiens (Human) 
2026-04-03 | PXD074954 | Pride
Paclitaxel-induced peripheral neuropathy is a significant problem, which afflicts up to 70% of chemotherapy patients. Therapeutic interventions are currently unavailable due to an incomplete understanding of the underlying mechanisms. We previously discovered a major target in the skin, MMP-13, whic...
ORGANISM(S): Mus musculus 
2021-10-12 | GSE185084 | GEO
Sort   by:  
 Page size